Your browser is no longer supported. Please, upgrade your browser.
Settings
ACRX AcelRx Pharmaceuticals, Inc. daily Stock Chart
ACRX [NASD]
AcelRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.82 Insider Own1.70% Shs Outstand78.28M Perf Week2.63%
Market Cap274.76M Forward P/E- EPS next Y-0.68 Insider Trans8.12% Shs Float69.61M Perf Month11.08%
Income-47.10M PEG- EPS next Q-0.22 Inst Own19.80% Short Float18.68% Perf Quarter38.74%
Sales2.20M P/S124.89 EPS this Y-117.40% Inst Trans0.39% Short Ratio6.09 Perf Half Y-15.42%
Book/sh0.06 P/B58.50 EPS next Y25.30% ROA-57.40% Target Price8.21 Perf Year44.74%
Cash/sh1.35 P/C2.60 EPS next 5Y- ROE145.80% 52W Range1.99 - 5.05 Perf YTD51.95%
Dividend- P/FCF- EPS past 5Y-6.50% ROI-32.50% 52W High-30.50% Beta2.13
Dividend %- Quick Ratio6.70 Sales past 5Y-40.80% Gross Margin-84.80% 52W Low76.38% ATR0.16
Employees61 Current Ratio6.80 Sales Q/Q-14.30% Oper. Margin- RSI (14)59.54 Volatility4.33% 4.56%
OptionableYes Debt/Eq24.58 EPS Q/Q-137.00% Profit Margin- Rel Volume0.95 Prev Close3.40
ShortableYes LT Debt/Eq22.49 EarningsMar 07 AMC Payout- Avg Volume2.14M Price3.51
Recom2.00 SMA203.95% SMA507.81% SMA20010.49% Volume2,034,749 Change3.24%
Feb-15-19Initiated Credit Suisse Outperform $7
Oct-23-18Initiated B. Riley FBR Buy $9
Oct-13-17Reiterated RBC Capital Mkts Outperform $6 → $5
Oct-13-17Downgrade Jefferies Buy → Hold
Jul-14-17Resumed Jefferies Buy $7
Sep-15-16Reiterated ROTH Capital Buy $11.25 → $15
Aug-05-16Downgrade Stifel Buy → Hold
Oct-30-15Upgrade Jefferies Hold → Buy
Oct-05-15Reiterated ROTH Capital Buy $8.50 → $10.50
Sep-02-15Initiated H.C. Wainwright Buy $8.50
Jul-10-15Resumed ROTH Capital Buy $7.50
May-06-15Reiterated Mizuho Neutral $5.50 → $3
May-05-15Reiterated RBC Capital Mkts Outperform $8 → $7
Mar-10-15Reiterated RBC Capital Mkts Outperform $12 → $8
Mar-09-15Downgrade Mizuho Buy → Neutral $14 → $5.59
Feb-26-15Upgrade Mizuho Neutral → Buy $6 → $14
Nov-06-14Downgrade Mizuho Buy → Neutral $15 → $6
Sep-26-14Downgrade ROTH Capital Buy → Neutral
Jul-28-14Reiterated RBC Capital Mkts Outperform $15 → $12
Jul-28-14Reiterated Mizuho Buy $20 → $15
Apr-20-19 09:06AM  Penny Stocks to Buy Using Technical Analysis for April 2019 Investopedia
Apr-11-19 04:37PM  AcelRx Pharmaceutical's pooled safety results for sufentanil sublingual tablets (DSUVIA) selected for presentation at 44th Annual Regional Anesthesiology & Acute Pain Medicine Meeting PR Newswire
Apr-09-19 11:05AM  Edited Transcript of ACRX earnings conference call or presentation 7-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
Apr-03-19 09:16AM  Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy Zacks
Mar-28-19 09:00AM  AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Mar-11-19 04:01PM  AcelRx Pharmaceuticals to Present at Oppenheimer & Co. Inc. 29th Annual Healthcare Conference PR Newswire -6.12%
Mar-08-19 12:03PM  Why AcelRx Pharmaceuticals Stock Is Sinking Today Motley Fool -13.03%
10:00AM  Here's Why Momentum Investors Will Love AcelRx Pharmaceuticals (ACRX) Zacks
Mar-07-19 04:01PM  AcelRx Pharmaceuticals Announces Commercial Launch of DSUVIA and Reports Fourth Quarter and Full Year 2018 Financial Results PR Newswire
Mar-04-19 10:43AM  3 Top Small-Cap Stocks to Buy Right Now Motley Fool
Feb-22-19 09:25AM  AcelRx to announce fourth quarter 2018 results and provide a corporate update on Thursday, March 7th, 2019 PR Newswire
Feb-19-19 10:00AM  Biotech Leaders to Watch This Week ACCESSWIRE +9.31%
09:35AM  4 Healthcare Stocks Looking to Start Strong on Tuesday (2/19/19) ACCESSWIRE
Feb-11-19 09:30AM  Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year? Zacks
Jan-31-19 07:00AM  AcelRx Pharmaceutical's sufentanil sublingual tablet (DSUVIA) to be highlighted during a presentation at the Boswick Burn and Wound Symposium PR Newswire
Jan-09-19 07:20AM  Investor Expectations to Drive Momentum within PulteGroup, Dave & Buster's Entertainment, AcelRx Pharmaceuticals, LSC Communications, PNM Resources, Inc. (Holding Co.), and H&E Equipment Services Discovering Underlying Factors of Influence GlobeNewswire
Jan-07-19 08:30AM  AcelRx Pharmaceuticals announces publication analyzing pooled data on sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain PR Newswire
Dec-27-18 09:23AM  2 Biotech Penny Stocks to Buy Right Now Motley Fool +7.31%
Dec-23-18 09:25PM  Hedge Funds Are Crazy About AcelRx Pharmaceuticals Inc (ACRX) Insider Monkey
Dec-21-18 08:51AM  Implied Volatility Surging for AcelRx Pharmaceuticals (ACRX) Stock Options Zacks
Dec-18-18 07:00AM  AcelRx Pharmaceuticals added to the NASDAQ Biotechnology Index (NBI) PR Newswire -5.56%
Dec-01-18 08:30AM  3 Stocks to Hold for the Next 20 Years Motley Fool
Nov-29-18 04:35PM  AcelRx Pharmaceuticals to Host Analyst and Investor Day on December 11 PR Newswire
Nov-21-18 09:25AM  New Healthcare Trends Could Push Sector Stocks Higher ACCESSWIRE
Nov-19-18 05:53PM  Edited Transcript of ACRX earnings conference call or presentation 5-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-14-18 04:05PM  AcelRx Pharmaceuticals to Present at the 17th Annual ASRA Pain Medicine Meeting PR Newswire -5.06%
Nov-09-18 01:43PM  Here's Why AcelRx Pharmaceuticals Lost as Much as 18.4% Today Motley Fool -16.11%
09:10AM  AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire
07:35AM  Report: Exploring Fundamental Drivers Behind AcelRx Pharmaceuticals, Fossil Group, FMC, Ultragenyx Pharmaceutical, Shenandoah Telecommunications, and Marcus & Millichap New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
07:00AM  AcelRx Pharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire
Nov-07-18 05:19PM  AcelRx Pharmaceuticals to Present at Credit Suisse 27th Annual Healthcare Conference PR Newswire -8.97%
Nov-06-18 07:44AM  Powerful new opioid 500 times stronger than morphine approved in U.S. in spite of outcry MarketWatch -8.67%
Nov-05-18 05:38PM  Health Care Digest: Health's push onto the ballot, an exec's cancer story and more American City Business Journals -11.04%
12:06PM  Why AcelRx Pharmaceuticals Stock Is Slipping Today Motley Fool
10:00AM  Monday's Top Healthcare Stocks To Watch Ahead Of Elections ACCESSWIRE
07:00AM  Todays Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and Sage Therapeutics ACCESSWIRE
06:40AM  3 Big Stock Charts for Monday: Coca-Cola, Kinder Morgan and Adobe InvestorPlace
Nov-02-18 07:19PM  Noting Military Potential, FDA Approves Powerful Painkiller Dsuvia The Wall Street Journal +15.66%
06:20PM  AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:17PM  AcelRx Pharmaceuticals: 3Q Earnings Snapshot Associated Press
04:05PM  AcelRx Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
04:04PM  Amid opioid concerns, FDA approves Peninsula company's powerful painkiller American City Business Journals
03:34PM  U.S. FDA approves AcelRx Pharma's opioid pain drug Reuters
01:56PM  AcelRx announces FDA approval of DSUVIA PR Newswire
01:47PM  AcelRx Pharma's opioid pain drug gets U.S. FDA nod Reuters
Nov-01-18 11:28AM  Will AcelRx Pharmaceuticals (ACRX) Report Negative Earnings Next Week? What You Should Know Zacks
Oct-26-18 08:55AM  Are Options Traders Betting on a Big Move in AcelRx Pharmaceuticals (ACRX) Stock? Zacks
Oct-24-18 02:57PM  On eve of FDA decision, Peninsula company battles backlash to pain-killing opioids American City Business Journals
09:52AM  On eve of FDA decision, Peninsula company battles backlash to pain-killing opioids American City Business Journals
Oct-23-18 03:07PM  As powerful new opioid nears FDA approval, critics ask if U.S. is stoking its drug crisis MarketWatch +10.67%
Oct-19-18 03:15PM  AcelRx Provides Updated Comments Following Positive FDA Advisory Committee Meeting PR Newswire -12.53%
10:02AM  Controversy builds over potent new opioid medication as U.S. senator calls on FDA to reject the drug MarketWatch
Oct-17-18 08:15AM  Report: Exploring Fundamental Drivers Behind CURO Group, BiondVax Pharmaceuticals, AMAG Pharmaceuticals, AcelRx Pharmaceuticals, Ballard Power, and Rhythm Pharmaceuticals New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire +5.29%
Oct-16-18 04:33PM  10 Hottest Stocks From October 16, 2018 Benzinga -7.46%
06:33AM  3 Biotechs Awaiting FDA Approval Decisions Motley Fool
Oct-15-18 04:01PM  DSUVIA Efficacy and Safety Data to be Presented at the American Society of Anesthesiologists (ASA) Annual Conference PR Newswire +7.79%
12:37PM  Stock Market News Daily Roundup October 15 Market Exclusive
12:11PM  Why AcelRx Pharmaceuticals Inc. Is Jumping Today Motley Fool
11:38AM  AcelRx's Dsuvia Gets FDA Committee Approval, Shares Rally Zacks
Oct-12-18 04:15PM  FDA Advisory Committee Recommends Approval Of DSUVIA For The Treatment Of Moderate-To-Severe Acute Pain PR Newswire
07:10AM  AcelRx Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review DSUVIA New Drug Application PR Newswire
Oct-11-18 08:00AM  Todays Research Reports on Stocks to Watch: Neovasc and AcelRx Pharmaceuticals ACCESSWIRE +10.71%
06:30AM  AcelRx Pharmaceuticals Inc. Is Soaring -- Should You Be Buying? Motley Fool
Oct-10-18 04:26PM  Why Analysts See Solid Upside Potential for Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX), and AcelRx (ACRX) SmarterAnalyst +35.66%
01:23PM  AcelRx shares surge after FDA staff says opioid safe Reuters
12:32PM  AcelRx Shares React Positively To FDA Committee Briefing On Painkiller Candidate Dsuvia Benzinga
12:20PM  FDA staff says AcelRx opioid painkiller safe and effective Reuters
Oct-08-18 07:30AM  The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs Benzinga
Sep-25-18 04:05PM  AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences in October PR Newswire -9.78%
08:00AM  Todays Research Reports on Stocks to Watch: Amarin Corporation and AcelRx Pharmaceuticals ACCESSWIRE
Sep-24-18 06:12PM  Here's Why AcelRx Pharmaceuticals, Inc. Jumped 16.5% on Monday Motley Fool +16.46%
Sep-11-18 07:00AM  AcelRx Announces Date of FDA Advisory Committee Meeting for DSUVIA PR Newswire
Sep-05-18 08:54AM  Are Options Traders Betting on a Big Move in AcelRx Pharmaceuticals (ACRX) Stock? Zacks
Aug-23-18 04:05PM  AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September PR Newswire
Aug-22-18 03:50PM  Edited Transcript of ACRX earnings conference call or presentation 2-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
07:50AM  New Research: Key Drivers of Growth for OncoSec Medical, AcelRx Pharmaceuticals, Cameco, Prestige Brand, Berry Global Group, and A-Mark Precious Metals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Aug-20-18 07:00AM  AcelRx Pharmaceuticals to Present at the 2018 Military Health System Research Symposium PR Newswire
Aug-16-18 11:19AM  AcelRX Shares Should More Than Double On Painkiller Assets, Landenburg Says In Bullish Initiation Benzinga +5.08%
Aug-09-18 09:30AM  Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year? Zacks
Aug-08-18 07:00AM  AcelRx Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire +7.02%
Aug-02-18 06:20PM  AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates Zacks
05:15PM  AcelRx Pharmaceuticals: 2Q Earnings Snapshot Associated Press
04:01PM  AcelRx Pharmaceuticals Reports Second Quarter 2018 Financial Results PR Newswire
02:30PM  AcelRx Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Jul-19-18 11:14AM  CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA Zacks
08:33AM  AcelRx to announce second quarter 2018 results and provide a corporate update on Thursday, August 2nd, 2018 PR Newswire
Jul-18-18 07:10AM  Free Technical Research on Medtronic and Three More Medical Equipment Equities ACCESSWIRE
Jul-13-18 01:56PM  Why You Shouldnt Get Too Excited About AcelRx Pharmaceuticals (ACRX) Stock SmarterAnalyst +8.47%
Jul-12-18 09:30AM  AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire -13.24%
08:37AM  Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial Benzinga
Jul-11-18 04:07PM  AcelRx Pharmaceuticals Announces Commencement of Public Offering of Common Stock PR Newswire
09:37AM  Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2 Zacks
09:14AM  VIVUS' PAH Candidate Data Positive in Early Stage Study Zacks
Jul-10-18 09:58AM  Aclaris' Alopecia Candidate Gets Fast Track Designation Zacks
Jul-02-18 09:04AM  Why this Peninsula drug company still is betting on pain for a gain American City Business Journals
Jun-27-18 07:00AM  AcelRx receives European Commission approval for DZUVEO PR Newswire
Jun-22-18 09:56AM  Shire (SHPG) HAE Drug Gets FDA Nod for Pediatric Population Zacks
Jun-18-18 07:05AM  Neovasc and Three Additional Medical Appliances & Equipment Stocks on Our Research Desks Radar ACCESSWIRE
Jun-15-18 11:28AM  Top Ranked Momentum Stocks to Buy for June 15th Zacks
Jun-12-18 12:19PM  Analyst: AcelRx Will Address FDA Concerns, Secure Approval This Year Benzinga
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EDWARDS MARK GDirectorMar 12Buy2.9919,00056,890200,000Mar 12 02:15 PM
ASADORIAN RAFFIChief Financial OfficerFeb 28Buy2.813,64710,248124,397Mar 04 04:28 PM
Dasu Badri NChief Engineering OfficerFeb 28Buy2.819,20625,869113,267Mar 04 04:26 PM
Angotti Vincent J.Chief Executive OfficerFeb 28Buy2.813,2349,088257,884Mar 04 04:25 PM
Hamel Lawrence GChief Development OfficerFeb 28Buy2.813,68210,34678,053Mar 04 04:24 PM
Palmer Pamela PChief Medical OfficerFeb 28Buy2.818402,360541,724Mar 04 04:23 PM
Angotti Vincent J.Chief Executive OfficerDec 14Buy2.783,61010,02454,650Dec 17 12:05 PM
ASADORIAN RAFFIChief Financial OfficerDec 14Buy2.785,00013,88352,000Dec 17 12:04 PM
Angotti Vincent J.Chief Executive OfficerDec 12Buy2.9910,00029,89051,040Dec 12 07:31 PM
Palmer Pamela PChief Medical OfficerNov 19Buy3.0716,00049,120472,134Nov 19 06:13 PM
EDWARDS MARK GDirectorNov 15Buy2.8220,70058,376181,000Nov 15 06:35 PM
ASADORIAN RAFFIChief Financial OfficerNov 13Buy3.135,00015,64647,000Nov 13 01:53 PM
Hamel Lawrence GChief Development OfficerOct 15Sale5.005,21626,08029,795Oct 16 04:30 PM
Dasu Badri NChief Engineering OfficerOct 15Sale5.0028,351141,75554,061Oct 16 04:29 PM
Hamel Lawrence GChief Development OfficerSep 24Sale4.506,95331,28935,011Sep 26 05:54 PM
Angotti Vincent J.Chief Executive OfficerAug 07Buy2.9010,00028,95035,000Aug 07 04:08 PM
EDWARDS MARK GDirectorAug 07Buy2.845,30015,063160,300Aug 08 04:36 PM
Palmer Pamela PChief Medical OfficerAug 06Buy2.7537,000101,750456,134Aug 06 05:38 PM
ASADORIAN RAFFIChief Financial OfficerAug 06Buy2.755,00013,72532,000Aug 06 05:23 PM
EDWARDS MARK GDirectorJun 05Buy3.354,70015,745155,000Jun 05 05:52 PM
EDWARDS MARK GDirectorJun 01Buy3.30300990150,300Jun 05 05:52 PM
ASADORIAN RAFFIChief Financial OfficerMay 25Buy3.185,00015,92327,000May 29 06:52 AM